Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy
Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana.
Gracell will present early clinical results of a first-in-human investigator-initiated trial (IIT) on GC502, an allogeneic CD19/CD7 dual-directed CAR-T cell therapy currently under development for multiple B-cell malignancy indications including B-cell acute lymphoblastic leukemia (B-ALL). GC502 is currently being studied in an open-label single-arm Phase 1 IIT in China for patients with B-ALL. This product candidate leverages the novel dual-directed CAR design of Gracell’s proprietary TruUCAR platform, which allows the CD19 CAR to target malignant cells, while the CD7 CAR is designed to suppress host-versus-graft rejection response.
Details of the presentation are as follows:
- Presentation Title: Early results of a safety and efficacy study of allogeneic TruUCAR GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
- Session Title: Phase I Clinical Trials 2
- Session Date and Time: Tuesday, April 12, from 9:00AM – 12:30PM CT
- Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 33
- Poster Board Number: 21
- Permanent Abstract Number: CT196
The full text of the abstract will be published to the AACR Online Itinerary Planner at 1:00PM ET on Friday, April 8. The e-poster will be viewable to registered attendees on the AACR’s e-poster website from Friday, April 8, through Wednesday, July 13. Additional meeting information is available on the AACR website.
Source: Gracell Biotechnologies Inc.